Ly3437943 Sodium

• A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting
  2025-522674-36-00 Phase III 15 countries Eli Lilly & Co.
• A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) Ended
  2024-511450-49-00 Phase III 2 countries Eli Lilly & Co.
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended
  2023-508630-34-00 Phase III 14 countries Eli Lilly & Co.
• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without T… Ended
  2023-504583-42-00 Phase II 2 countries Eli Lilly & Co.
• A Study of LY3437943 in Participants Who Have Obesity or Overweight (TRIUMPH-1) Ended
  2023-503657-35-00 Phase III 4 countries Eli Lilly & Co.
• A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4) Ended
  2023-503660-17-00 Phase III 1 country Eli Lilly & Co.
• A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Ended
  2023-503659-88-00 Phase III 4 countries Eli Lilly & Co.
• A Study of LY3437943 in Participants with Type 2 Diabetes Mellitus who have Obesity or Overweight (TRIUMPH-2) Ended
  2023-503658-11-00 Phase III 2 countries Eli Lilly & Co.
• A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain ( TRIUMPH-7 ) Ended
  2024-517431-43-00 Phase III 1 country Eli Lilly & Co.

Showing 1–9 of 9 trials